Trial reportKorean journal of anesthesiology2025
Comparison of remimazolam and sevoflurane on arterial oxygenation during one-lung ventilation in thoracoscopic surgery: a randomized controlled trial.
Trial report in Korean journal of anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne-lung ventilation (OLV) during thoracoscopic surgery can impair oxygenation due to increased intrapulmonary shunts. Remimazolam has gained attention for its hemodynamic stability and rapid recovery profile; however, its effects on arterial oxygenation during OLV remain unclear. This study aimed to compare the effects of remimazolam and sevoflurane on arterial oxygenation during OLV.
methodsIn this prospective, randomized controlled trial, 58 adult patients undergoing thoracoscopic surgery were assigned to receive either sevoflurane or remimazolam for anesthesia maintenance. Arterial blood gas analysis and hemodynamic parameters were measured at four time points: 10 min after lateral positioning during two-lung ventilation (TLV10) and 15, 30, and 60 min after initiating OLV (OLV15, OLV30, and OLV60). The primary outcome was arterial partial pressure of oxygen (PaO2) at OLV30. Secondary outcomes included time-dependent changes in PaO2, hemodynamic variables, and serum lactate levels.
resultsNo significant difference in PaO2 at OLV30 was observed between groups (108.9 ± 37.9 vs. 107.0 ± 37.8 mmHg, 95% CI [-21.8 to 18.0], P = 0.815). In within-group analysis, PaO2 at OLV60 increased significantly from TLV10 in the remimazolam group (95% CI [0.3-36.8], P = 0.044), while no such improvement was observed in the sevoflurane group. Serum lactate levels exhibited a significant time-by-group interaction with a greater reduction in the remimazolam group (P = 0.021).
conclusionsRemimazolam provided arterial oxygenation and hemodynamic stability comparable to sevoflurane during OLV. The greater reduction in serum lactate levels with remimazolam suggests its potential metabolic or immunomodulatory advantages that warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.